Bath scientists stabilise vaccine proteins with ensilication
A new system for delivering vaccines to children in low-income nations has taken a vital step forward, thanks to groundbreaking work at the University of Bath
Vaccines are notoriously difficult to transport to remote or dangerous places, as they spoil when not refrigerated. Formulations are safe between 2°C and 8°C, but at other temperatures the proteins start to unravel, making the vaccines ineffective. As a result, millions of children around the world miss out on life-saving inoculations.
However, scientists have now found a way to prevent warmed-up vaccines from degrading. By encasing protein molecules in a silica shell, the structure remains intact even when heated to 100°C, or stored at room temperature for up to three years.
The technique for tailor-fitting a vaccine with a silica coat – known as ensilication – was developed by a Bath team in collaboration with the University of Newcastle. This pioneering technology was seen to work in the lab two years ago, and now it has demonstrated its effectiveness in the real world too.
The researchers explain the significance of their findings
In their latest study, published in the journal Scientific Reports, the researchers sent both ensilicated and regular samples of the tetanus vaccine from Bath to Newcastle by ordinary post (a journey time of over 300 miles, which by post takes a day or two). When doses of the ensilicated vaccine were subsequently injected into mice, an immune response was triggered, showing the vaccine to be active. No immune response was detected in mice injected with unprotected doses of the vaccine, indicating the medicine had been damaged in transit.
Dr Asel Sartbaeva, who led the project from the University of Bath’s Department of Chemistry, said: “This is really exciting data because it shows us that ensilication preserves not just the structure of the vaccine proteins but also the function – the immunogenicity.”
“This project has focused on tetanus, which is part of the DTP (diphtheria, tetanus and pertussis) vaccine given to young children in three doses. Next, we will be working on developing a thermally-stable vaccine for diphtheria, and then pertussis. Eventually we want to create a silica cage for the whole DTP trivalent vaccine, so that every child in the world can be given DTP without having to rely on cold chain distribution.”
Cold chain distribution requires a vaccine to be refrigerated from the moment of manufacturing to the endpoint destination.
Silica is an inorganic, non-toxic material, and Dr Sartbaeva estimates that ensilicated vaccines could be used for humans within five to 15 years. She hopes the technology to silica-wrap proteins will eventually be adopted to store and transport all childhood vaccines, as well as other protein-based products, such as antibodies and enzymes.
“Ultimately, we want to make important medicines stable so they can be more widely available,” she said. “The aim is to eradicate vaccine-preventable diseases in low income countries by using thermally stable vaccines and cutting out dependence on cold chain.”
Currently, up to 50% of vaccine doses are discarded before use due to exposure to suboptimal temperatures. According to the World Health Organisation (WHO), 19.4 million infants did not receive routine life-saving vaccinations in 2018.
The Latest Updates from Bing News & Google News
Go deeper with Bing News on:
- Translate Bio Joins With Sanofi to Make Covid Vaccineson June 23, 2020 at 10:06 am
Sanofi will take a 7.2% stake in Translate Bio as part of the deal and give it an initial $425 million payment.
- US taxpayers are funding six COVID-19 vaccines; Here’s how they workon June 23, 2020 at 10:03 am
Here’s an explanation of where this money is going. First, a short explanation of how vaccines work. When your body is attacked by a virus, your immune system makes antibodies to fight it off.
- Nearly 150 Potential Coronavirus Vaccines Are Being Developed Globallyon June 23, 2020 at 9:58 am
As the COVID-19 pandemic continues, at least 142 potential novel coronavirus vaccines are being developed by researchers across the globe, the World Health Organization (WHO) confirms. Thirteen ...
- Scientists make step forward in development of COVID-19 animal vaccineson June 23, 2020 at 9:37 am
Scientists have made significant steps in the development of vaccines that could be used to tackle COVID-19 in animals.
- Sanofi Expands Agreement With Translate Bio for mRNA Vaccineson June 23, 2020 at 9:23 am
Sanofi SNY announced that it has agreed to expand its collaboration deal with Translate Bio TBIO to develop novel messenger RNA (mRNA) vaccines for several infectious diseases. We note that Translate ...
Go deeper with Google Headlines on:
Go deeper with Bing News on:
- Tech to keep vaccines from heat damageon June 16, 2020 at 3:35 pm
"The aim is to eradicate vaccine-preventable diseases in low income countries by using thermally stable vaccines and cutting out dependence on cold chain," stated Dr Sartbaeva. In Kenya ...
- This New Method To Stabilize Vaccines Without Refrigerators Could Help Slow Global Epidemicson June 12, 2020 at 12:55 pm
The proteins within vaccines will begin to degrade in room temperature. When the proteins degrade, the vaccine loses its ability to immunize a patient. A new paper shows how a method called ...
- Distinct neutralizing antibody correlates of protection among related Zika virus vaccines identify a role for antibody qualityon June 10, 2020 at 11:29 am
1 Laboratory of Viral Diseases, NIAID, NIH, Bethesda, MD 20892, USA. 2 Vaccine Research Center, NIAID, NIH, Bethesda, MD 20892, USA. 3 Ragon Institute, Cambridge, MA ...
- Vaccine-Coating Tech Could Help Millions More Children Receive Immunizationon June 9, 2020 at 5:00 am
Scientists suggest that using ensilication tech to protect vaccines against temperature-related degradation could stop up to half of global vaccine doses needing to be discarded ...
- Breakthrough In Vaccine Development Creates Thermally Stable Medicationson June 8, 2020 at 12:14 pm
The researcher’s intent to continue developing thermally stable vaccines for diseases such as diphtheria and pertussis. "Ultimately, we want to make important medicines stable so they can be ...